New dosing for Janssen's Incivo to boost compliance, but what about sales?
This article was originally published in Scrip
Executive Summary
Janssen's HCV treatment Incivo/Incivek (telaprevir) can now be taken in the EU in two daily doses rather than three. The European Commission has become the first regulator to approve the new dosing, which aligns it with the twice-daily dosing schedule for ribavirin.